Home›Trial›NCT02988960
🔬NCT02988960Phase 1ACTIVE NOT RECRUITING

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

Study Summary

This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.

Conditions
Advanced Solid Tumors Cancer
Interventions / Drugs
ABBV-927ABBV-927ABBV-181
View on ClinicalTrials.gov ↗
Sponsor
ABBV
AbbVie Inc
Immunology
C64/100
Study Details
Enrollment163 participants
Primary Completion—
Lead SponsorAbbVie
Data Retrieved2026-04-11 02:51:51.325249+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.